Trending...
- Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
- Retired Hobbyist Launches Bold Weekly Album Project Using AI Songwriting Tools
- 216 Marketing Launches New Website to Help Local Businesses Dominate Online in Northeast Ohio
DAYTON, Ohio, Sept. 9, 2021 /PRNewswire/ -- Soin Therapeutics, a pharmaceutical company based in Dayton, OH, was granted orphan drug status from the FDA for low dose naltrexone (LDN) to treat complex regional pain syndrome (CRPS).
Complex Regional Pain Syndrome is a rare, orphan disease that is characterized by severe pain, usually starting in an extremity, and associated with extreme swelling, limited range of motion, changes to skin or bone structure and debilitating pain.
Naltrexone is a medication that is primarily used to manage alcohol or opioid use disorder by reducing cravings or feelings of euphoria associated with substance use disorder. It has also been shown in anecdotal reports to alleviate symptoms stemming from CRPS at very low doses (approximately 1/10th the dose) of currently approved indications. When the dose of the drug is substantially lowered, the pharmacological effects change favorably to treat CRPS.
More on Ohio Pen
"Obtaining Orphan Status from the FDA is an important milestone step for us at Soin Therapeutics. We look forward to running a large-scale clinical trial and eventually FDA approval to help patients suffering from CRPS", noted Dr. Amol Soin, the founder and CEO of Soin Therapeutics. Dr Soin, a practicing pain management physician, has seen firsthand the suffering that CRPS patients experience. CRPS is a disease without a cure and there is a lack of any viable treatments which led Soin to look deeper at LDN as a potential treatment.
"Low Dose Naltrexone has unique properties to specifically help the disease cascade of CRPS including attenuation of microglial cells involved in pain transmission, reduction of proinflammatory cytokines, antagonism of the Toll-like receptor 4 (TLR4), as well as stimulating release of endorphins which are the body's natural pain killers. Basically, this drug seems very well suited to treat several mechanisms of the disease process. All those properties would seemingly be quite helpful in CRPS patients. Best of all, this is a non-addicting and non-sedating drug that could be a new way to treat complex regional pain syndrome", Soin said.
More on Ohio Pen
Currently, Soin Therapeutics is developing its own novel formulation of LDN and is in the process of preparing a pre-IND (Investigational New Drug application) meeting with FDA as a needed step to commence a large, multicenter, national clinical trial.
About Soin Therapeutics: Soin Therapeutics Inc. (STI) is a pharmaceutical company founded by Dr. Amol Soin, a pain management physician from Dayton, OH. STI is currently developing low dose naltrexone to treat complex regional pain syndrome and has received an orphan drug designation from the FDA.
About Amol Soin: Dr. Amol Soin is a physician researcher and entrepreneur in the field of pain management. Currently, Soin is the president of ASIPP (American Society of Interventional Pain Physicians) and is in private practice. Dr. Soin has founded multiple biotech start-up companies, holds multiple patents and has published over 100 scholarly articles, abstracts, and textbook chapters in the field of pain management.
SOURCE Soin Therapeutics
Complex Regional Pain Syndrome is a rare, orphan disease that is characterized by severe pain, usually starting in an extremity, and associated with extreme swelling, limited range of motion, changes to skin or bone structure and debilitating pain.
Naltrexone is a medication that is primarily used to manage alcohol or opioid use disorder by reducing cravings or feelings of euphoria associated with substance use disorder. It has also been shown in anecdotal reports to alleviate symptoms stemming from CRPS at very low doses (approximately 1/10th the dose) of currently approved indications. When the dose of the drug is substantially lowered, the pharmacological effects change favorably to treat CRPS.
More on Ohio Pen
- Paul E. Saperstein Co. Announces Geographic Expansion of Auction Services
- 216 Marketing Launches New Website to Expand Local SEO and Digital Marketing Services
- Florida Broker Bent Danholm Featured in the Daily Mail's U.S. Real Estate Coverage
- Robin Launches Legal Intelligence Platform to solve intelligence gap in Fortune 500 legal teams
- Melissa B. Releases Digitally Independent: Empowering Music Artists with AI and Brand Strategy
"Obtaining Orphan Status from the FDA is an important milestone step for us at Soin Therapeutics. We look forward to running a large-scale clinical trial and eventually FDA approval to help patients suffering from CRPS", noted Dr. Amol Soin, the founder and CEO of Soin Therapeutics. Dr Soin, a practicing pain management physician, has seen firsthand the suffering that CRPS patients experience. CRPS is a disease without a cure and there is a lack of any viable treatments which led Soin to look deeper at LDN as a potential treatment.
"Low Dose Naltrexone has unique properties to specifically help the disease cascade of CRPS including attenuation of microglial cells involved in pain transmission, reduction of proinflammatory cytokines, antagonism of the Toll-like receptor 4 (TLR4), as well as stimulating release of endorphins which are the body's natural pain killers. Basically, this drug seems very well suited to treat several mechanisms of the disease process. All those properties would seemingly be quite helpful in CRPS patients. Best of all, this is a non-addicting and non-sedating drug that could be a new way to treat complex regional pain syndrome", Soin said.
More on Ohio Pen
- Consumer Accountability Alliance Issues Formal Notice Alleging Proximate Liability for Medical Harm
- Utah Metal Fabricator Titan Forge Builds Momentum with Custom Steel Projects and Spiral Staircases
- Jason Koch: Pioneering the Future of Real Estate Development in New Jersey
- CameraSecurityNow.com Introduces Verkada's AI-Powered Search for Faster, Smarter Footage Analysis
- Bach and Beyond: Cellists Return to the Beach for 2nd Annual Bethany Beach Cellofest
Currently, Soin Therapeutics is developing its own novel formulation of LDN and is in the process of preparing a pre-IND (Investigational New Drug application) meeting with FDA as a needed step to commence a large, multicenter, national clinical trial.
About Soin Therapeutics: Soin Therapeutics Inc. (STI) is a pharmaceutical company founded by Dr. Amol Soin, a pain management physician from Dayton, OH. STI is currently developing low dose naltrexone to treat complex regional pain syndrome and has received an orphan drug designation from the FDA.
About Amol Soin: Dr. Amol Soin is a physician researcher and entrepreneur in the field of pain management. Currently, Soin is the president of ASIPP (American Society of Interventional Pain Physicians) and is in private practice. Dr. Soin has founded multiple biotech start-up companies, holds multiple patents and has published over 100 scholarly articles, abstracts, and textbook chapters in the field of pain management.
SOURCE Soin Therapeutics
Filed Under: Business
0 Comments
Latest on Ohio Pen
- New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
- The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side
- Digital Watchdog Launches New myDW Cloud Services
- Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter
- Drone Light Shows Emerge as the New Standard in Live Event Entertainment
- Lore Link is Here to Help Organize Your Game
- Chappaqua's Annual Townwide Summer Sale – Unbeatable Savings at Your Favorite Local Boutiques!
- 216 Marketing Launches New Website to Help Local Businesses Dominate Online in Northeast Ohio
- Skyline Partners with ZenSpace to Offer Private Meeting Pods for Trade Show Exhibitors
- Powerful Stories and Shared Sisterhood Shine at "An Evening with the Author" Featuring Staci Kirk
- AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
- Champions Group Expands Midwest Presence with Acquisition of McAfee Heating and Air Conditioning
- Construcción del Corredor Norte–Sur (NSC) de Singapur
- New Report: Slip and Fall Accidents Rank as the Leading Cause of Construction Site Fatalities
- Get Your Cowboy Boots On! Causeway Country BBQ Music Festival Kicks Off September 12–14 in Ft. Pierce
- Retired Hobbyist Launches Bold Weekly Album Project Using AI Songwriting Tools
- DimHum Launches Revolutionary CrowdShipping Service
- Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
- Infinite Health Introduces Cutting-Edge Regenerative Medicine for Wound Care with Trip Goolsby, MD
- Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews